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Abstract
Background: People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV). Treatment options
are improving and may enhance prevention; however access for PWID may be poor. The availability in the literature of
information on seven main topic areas (incidence, chronicity, genotypes, HIV co-infection, diagnosis and treatment uptake,
and burden of disease) to guide HCV treatment and prevention scale-up for PWID in the 27 countries of the European Union
is systematically reviewed.
Methods and Findings: We searched MEDLINE, EMBASE and Cochrane Library for publications between 1 January 2000 and
31 December 2012, with a search strategy of general keywords regarding viral hepatitis, substance abuse and geographic
scope, as well as topic-specific keywords. Additional articles were found through structured email consultations with a large
European expert network. Data availability was highly variable and important limitations existed in comparability and
representativeness. Nine of 27 countries had data on HCV incidence among PWID, which was often high (2.7-66/100 person-
years, median 13, Interquartile range (IQR) 8.7–28). Most common HCV genotypes were G1 and G3; however, G4 may be
increasing, while the proportion of traditionally ‘difficult to treat’ genotypes (G1+G4) showed large variation (median 53, IQR
43–62). Twelve countries reported on HCV chronicity (median 72, IQR 64–81) and 22 on HIV prevalence in HCV-infected
PWID (median 3.9%, IQR 0.2–28). Undiagnosed infection, assessed in five countries, was high (median 49%, IQR 38–64), while
of those diagnosed, the proportion entering treatment was low (median 9.5%, IQR 3.5–15). Burden of disease, where
assessed, was high and will rise in the next decade.
Conclusion: Key data on HCV epidemiology, care and disease burden among PWID in Europe are sparse but suggest many
undiagnosed infections and poor treatment uptake. Stronger efforts are needed to improve data availability to guide an
increase in HCV treatment among PWID.
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Introduction
Chronic infection with the hepatitis C virus (HCV) affects about
160 million people worldwide [1,2]. In developed countries,
iatrogenic transmission of this blood-borne virus has been
substantially reduced and people who inject drugs (PWID), or
those who have done so in the past, are now the main group
affected [3–6].
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HCV infection is a serious public health problem as chronically
infected individuals are at risk for long-term sequelae, including
liver cirrhosis and hepatocellular carcinoma [7]. Indeed, in
Europe, HCV is a leading cause of cirrhosis and primary liver
cancer [8]. Since 2001, effective treatment with pegylated
interferon and ribavirin has been available. In recent years, there
have been advances in treatment with the development of direct
acting antiviral (DAA) therapy [9]. PWID in many countries still
have limited access to HCV treatment, despite multiple studies
providing evidence that this population can be successfully treated
[10–17] only 1–6% of HCV-infected current and former PWID in
the United States, Canada, and Australia were treated [14–16,18–
20]. The low uptake of treatment among PWID is due to both
physician and patient-associated factors. Firstly, physicians’
concerns about adherence, other co-morbidities including HIV
co-infection, treatment side-effects and the potential for re-
infection may lead to treatment being withheld [5,10,21,22].
Secondly, poverty, psychiatric co-morbidities, poor social support
and stigma are common among PWID and may result in HCV
treatment not being viewed as a priority for them [23–25]. Other
barriers may relate to educational level, problems with accessing
diagnostic tests (e.g. in non-urban regions or when access to
primary care is difficult), and entering specialist referral pathways
[26,27].
Treatment is likely to have a synergistic impact on HCV
prevention efforts. Modelling studies suggest that antiviral
treatment could play an important, and cost-effective, role in
preventing HCV in PWID by reducing the number at risk of
transmitting HCV [28–31].
In Europe, many countries have implemented harm reduction
programmes [32,33] as well as health insurance systems to cover
treatment costs of PWID (several including DAA). Therefore,
access to HCV treatment should be feasible [34,35] and recent
European clinical guidelines state it must be considered for PWID
[36]. Although national treatment guidelines have varied substan-
tially and have often been highly restrictive with regard to PWID
[37,38], the experience in some European countries has shown
that it is possible to expand HCV diagnosis, prevention and
treatment of PWID [6,34,39–42]. Key data elements to inform
HCV treatment scale-up for PWID cover epidemiological data on
the prevalence, dynamics and characteristics of the epidemic,
estimates of future burden of disease and associated healthcare
needs [39,43–47].
To assess data availability for informing a potential future scale
up of HCV treatment (including ‘treatment for prevention’)
among PWID in Europe, we performed a systematic review of the
literature published between 2000–2012, covering the epidemiol-
ogy of HCV infection, treatment uptake and estimates of the
future burden of disease among PWID in European countries (the
EU 27) to complement existing routinely collated data (for
example on antibody prevalence and harm reduction service
provision as collected by EMCDDA – see Table S2 in Web-
appendix S1) [4,44,48,49]. Most of these data might be equally
important to informing overall HCV prevention policies. (Further
detail on the rationale and importance of these data for HCV
treatment and prevention policies is given in Table 1 and
Discussion, while Table 2 summarises what this study adds to
current knowledge.).
Our overall research question was: ‘What data is available in
European Union countries to inform a potential scale-up of HCV
treatment (for prevention) among PWID?’ This was operationa-
lised into five specific questions, covering seven topic areas, all
limited to HCV infection among PWID in Europe:
1) What is the incidence of infection?
2) What proportion of infections become chronic?
3) What are infection characteristics, in terms of genotypes and
HIV co-infection?
4) What proportions of infected are undiagnosed and, of those
diagnosed, enter antiviral treatment?
5) What estimates exist of the future burden of disease?
Methods
Seven separate systematic reviews of the literature were
performed, covering HCV incidence, chronicity rates, genotype
distribution, HIV co-infection, undiagnosed chronic hepatitis C
(CHC) cases, HCV treatment uptake, and burden of disease.
Study references were identified through searches of MEDLINE,
EMBASE and the Cochrane Library databases for articles
published in any language between 1 January 2000 and 31
December 2012. A standard search strategy was agreed (Web-
appendix S1) with general keywords regarding viral hepatitis,
substance abuse and geographic scope (Table 3), as well as seven
search strings with topic area-specific keywords. Additional articles
were found through structured email consultations with a large
European expert network (on substance use and infectious
diseases, including viral hepatitis (see Acknowledgments)) covering
each of the 27 countries (Table 4). The protocol was consistent
with the PRISMA criteria [58]. Search results per topic area were
screened for relevance independently by two researchers on the
basis of title and abstract and results compared, retaining articles
in case of doubt. Duplicates between the three databases were
removed. The remaining articles were retrieved and evaluated
independently by two researchers on the basis of the full article
text using agreed selection criteria across all seven topic areas.
Studies were included for the 27 EU member states. Non-English
articles were evaluated with the help of native speakers, country
experts and online translation services (Google Translate and
BabelFish) and if necessary and possible by contacting the authors.
Additional inclusion criteria were reporting data collected since
1990 (except for Burden of disease, due to the long-term
perspective of modelling projections). Quality criteria for inclusion
(Web-appendix S1) were to have a clearly defined study
population of PWID only (having ever injected drugs) or data
provided for PWID separately, consistency and clarity of the data
reported and an unselected sample of PWID with regard to gender
or HBV/HIV co-infection (except for Burden of disease, where
due to the small number of studies found, two studies based on
HIV co-infected samples were included). Sample sizes below
n = 10 were excluded except if they provided the only data for a
country on a topic area. For articles excluded in this phase the
reasons for this were noted. Data were extracted from the
remaining articles into tables for each of the topic areas (Tables
S3–S10 in Web-appendix S2) and the reference lists were checked
for further studies. Multiple publications for one study were
consolidated and treated as one entry, in order to maximise
information available per study. Data were presented untrans-
formed (Incidence, Burden of disease) or, where possible, pooled
weighted prevalences (median, average, range in %) were
calculated per country (Chronicity, Genotypes, Co-infection,
Diagnosis, Treatment entry) and study type/setting (Incidence,
Chronicity, Diagnosis, Treatment entry). Data availability per
country was crudely assessed by the number of (out of seven) topic
areas where data were available (Table 4). For Genotypes the sum
of the proportions of ‘difficult to treat’ genotypes (1 and 4)
[36,59,60] is presented (Table 4). For Co-infection the correlation
HCV among People Who Inject Drugs in Europe
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was assessed with HIV prevalence. Overall, a meta-analysis was
considered outside the scope of this review, although for one topic
(Chronicity) a limited analysis was performed (Web-appendix S3).
Results
Overall the systematic search retrieved 2,955 references to
publications. After removal of duplicates and clearly irrelevant
references, we screened 1,552 references on the basis of title and
abstract. 528 articles were retrieved and obtained in full text, of
which 144 were included in the quantitative synthesis. The step-
wise description of selection and inclusion of studies is depicted in
a flowchart in Figure 1. Followed below are detailed study
questions, main findings and results for each of the seven topic
areas reviewed.
Incidence
Study questions. What is the incidence of HCV infection
among PWID in Europe and how has this been measured? How
does incidence vary between countries?
Main findings. Data are sparse across Europe and are not
easily comparable. The data suggests that incidence is highly
variable in the populations studied (Figure 2).
Studies included. Studies were included that had directly
measured incidence of hepatitis C infection in PWID, by using one
of the following approaches: 1) a cohort or follow-up study 2)
detection of HCV RNA in the absence of anti-HCV in a cross-
sectional study 3) assessing anti-HCV avidity in a cross-sectional
study. Studies that had indirectly estimated incidence from HCV
prevalence data, for example using force of infection calculations,
were excluded. 27 studies, from nine countries, reported the
incidence of primary HCV infection (Czech Republic, Denmark,
Ireland, Finland, France, Netherlands, Sweden, Spain, UK;
Table 4). Four countries had undertaken more than one (Czech
Republic, Ireland, Sweden, UK); most studies had been under-
taken in UK (n = 16, 59%). Three studies measured re-infection
(Germany, Netherlands, UK; Table 4) (Table S3 in Web-
appendix S2). [61–89].
Study design. Incidence of primary HCV infection had been
measured in 17 follow-up studies, and in ten cross-sectional studies
(nine used HCV RNA in the absence of anti-HCV and one anti-
HCV avidity to estimate HCV incidence).
Population. For primary HCV infection, three studies
recruited PWID from community settings, 19 through health
services (including needle and syringe programmes) and three
from both settings. Two were in custodial settings. The re-infection
studies were in clinical settings.
Findings. The number of PWID at risk of primary infection
in studies undertaken outside of custodial settings ranged from 27
(Spain, ‘new PWID’: injecting less than 2 years) [68] to 2,532 (UK,
‘ever PWID’: having ever injected drugs) [82]; (median:168
people; mean 424). The measured incidence of primary HCV
infection varied from 2.7–3.2/100PY in one UK study (ever
PWID) [82] to 66/100PY in a study from Ireland (ever PWID)
[66]. The median incidence was 13/100PY (Interquartile range
(IQR) 8.7–28, mean 19/100PY). In the eleven studies only
including current/recent PWID the incidence was higher than in
the remaining studies (median 26/100PY IQR 9.4–35 vs. median
12/100PY IQR 9.0–16), and ranged from 5.2/100PY years to 42/
100PY (both UK) [74,85]. The two studies in custodial settings
were small, with only eight (25/100PY, Denmark, ever PWID)
[86] and 69 (12/100PY, UK, ever PWID) [76,87] participants.
The three small studies of HCV re-infection reported incidences of
Table 1. Data items reviewed and their rationale for HCV policy.
1. HCV incidence in PWID: complement available prevalence data by giving an estimate for level of recent infections, a direct measure of (treatment for) prevention
effectiveness as well as being important for future burden estimates.
2. Chronicity of infections: allow interpreting antibody prevalence data in terms of current and projected future prevalence of infection and treatment need.
3. Genotypes: predictor of current treatment outcomes, Genotypes 1 and 4 are traditionally hard to treat. New treatments may overcome this problem but are not yet
implemented at scale and there are important costs issues.
4. HIV co-infection: predictor of current treatment outcomes and mortality (new treatments may overcome this: see previous point).
5. Undiagnosed proportion: extent of under-diagnosis and linkage to care and treatment.
6. Treatment entry: measure of treatment coverage and accessibility.
7. Burden of disease: projections of future costs to the health care system and wider society, important when considering investment into treatment
doi:10.1371/journal.pone.0103345.t001
Table 2. What is known and what this study adds.
1. More specialised reviews have been carried out [43,50–56], but no systematic review has provided a comprehensive overview [57], across multiple topic areas, of
available data to inform hepatitis C treatment scale-up (including prevention) among PWID in a large region of the world.
2. Our review found that the majority of available studies published between 2000–2012 focused on HCV prevalence, treatment and on the genotype characterisation
of patients with HCV, while very few investigated the burden of disease. In some of the topic areas data was scarce, in particular for recent years (2006–2012).
3. Incidence of HCV infection in PWID in the EU varies greatly, but can be as high as 66/100 person years (PY). Chronicity rates vary both above and under the expected
75% [56]. Genotypes 1 and 3 predominate among PWID, but 4 appears to be increasing, while the proportion of ‘difficult to treat’ genotypes (1+4) shows large variation
(17–91%, median 53%). The prevalence of HIV co-infection in HCV-infected PWID varies widely (0–70%, median 3.9%), correlating closely with but generally higher than
overall HIV prevalence among PWIDs.
4. Half of the chronically infected PWID were unaware of their infection, and, of those diagnosed, only one in ten entered treatment for Hepatitis C.
5. This study highlights major information gaps regarding epidemiology, diagnosis, treatment entry and burden of disease of hepatitis C infection in PWID in most
European Union countries, potentially hampering HCV treatment scale up.
doi:10.1371/journal.pone.0103345.t002
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6.9/100PY following a negative HCV RNA test result (N = 347,
UK, ever PWID) [83], 3.4/100PY (N = 11, Netherlands, ever
PWID) [88] and 0–4.1/100PY following treatment induced viral
clearance (N = 18, Germany, ever PWID) [89].
Chronicity
Study questions. What is the prevalence of chronic HCV
infection among anti-HCV positive PWID in Europe? How does
chronicity vary by setting, demographics, duration of injecting,
and co-infection status?
Main findings. Available data on HCV-RNA rates in anti-
HCV positive PWID show considerable variation (Table 4,
Figure 3).
Studies included. Twenty-seven studies met the inclusion
criteria [81,82,90–116] from fourteen countries (Table 4). These
investigated the prevalence of HCV-RNA in 28 populations which
included 10,263 anti-HCV positive PWID. Three additional
studies were included that investigated the development of chronic
infection in 98 PWID acutely infected with HCV [117–119].
(Table S4 in Web-appendix S2).
Study design. Nine cohort studies [100,103,105,109,113,
115,117–119], and 21 cross-sectional studies tested HCV-RNA
using PCR as a marker for chronic infection [81,82,90–
99,101,102,104,106–108,111,112,114,116].
Population. PWID were recruited in drug treatment centres,
general practices, gastroenterology and hepatology units, infec-
tious diseases and genitourinary medicine clinics, and in the
community.
Findings. The level of chronic infection in anti-HCV positive
PWID ranged between 53% and 97% with a median of 72% (IQR
64–81%). The proportion of acute HCV infections among PWID
progressing to chronic infection varied between 0% and 56%.
Based on seven studies with mean age [90,91,96,103,
106,111,115] and four studies with mean duration of injecting
drug use of the anti-HCV positive PWID [91,96,111,113] a
significant positive linear relation was observed between chronicity
rate and both mean age of the population (Regression coeffi-
cient = 0.14; 95% CI: 0.00–0.28; P = 0.046) and mean duration of
injecting drug use (Regression coefficient = 0.18; 95% CI: 0.02–
0.34; P = 0.026). Based on the results of three studies [92,110,116]
Table 3. Search terms used.
General terms across all topic areas: (‘‘Substance Abuse, Intravenous’’[Mesh] OR ‘‘IDU’’ OR ‘‘IDUs’’ OR ‘‘PWID’’ OR ‘‘IVDU’’ OR ‘‘IVDUs’’ OR ‘‘intravenous drug’’ OR ‘‘injecting
drug’’ OR ‘‘intravenous substance’’ OR ‘‘Injection drug’’ OR ‘‘inject drugs’’) AND (‘‘Hepatitis C’’[Mesh] OR ‘‘hepatitis C’’ OR ‘‘HCV’’) as well as country specific terms.
Additional search strings per topic area: 1) Incidence: ‘‘incidence’’, 2) Chronicity: HCV-RNA[All Fields] OR (‘‘genotype’’[MeSH Terms] OR ‘‘genotype’’[All Fields]) OR
persistence[All Fields] OR (‘‘viraemia’’[All Fields] OR ‘‘viremia’’[MeSH Terms] OR ‘‘viremia’’[All Fields]), 3) Genotype: ‘‘genotype’’[tiab] OR ‘‘subtype’’[tiab] OR ‘‘molecular
epidemiology’’ [tiab], 4) Co-infection: HIV or ‘‘HIV’’[Mesh] or ‘‘hiv*’’, 5) Diagnosis: ‘‘test’’[tiab] OR ‘‘prevalence’’[tiab] OR ‘‘proportion’’[tiab] OR ‘‘referral’’[tiab] OR
‘‘trend’’[tiab] OR ‘‘screening’’[tiab] OR ‘‘diagnostics’’[tiab] OR ‘‘surveillance’’[tiab] OR ‘‘unidentified’’[tiab] OR ‘‘diagnosis’’[tiab] OR ‘‘undiagnosed’’[tiab], 6) Treatment:
‘‘antiviral’’[tiab] OR ‘‘treatment’’[tiab] OR ‘‘therapeutics’’[tiab] OR ‘‘access to treatment’’[tiab], 7) Burden of Disease: Cost-effectiv* [tiab] OR burden [tiab] OR daly [tiab] OR
qaly[tiab] OR morbidity [tiab] OR mortality[tiab] OR ‘‘Cost of Illness’’[Mesh] OR illness cost*[tiab] OR incremental cost-effectiveness ratio [tiab] OR Cost-Benefit Analysis
[Mesh].
Country specific terms: Web-appendix S1.
doi:10.1371/journal.pone.0103345.t003
Figure 1. Flow diagram of study selection aggregated over the seven topic areas reviewed.
doi:10.1371/journal.pone.0103345.g001
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a significant relationship between HIV-co-infection (OR 1.67,
95% CI 1.07–2.60; P = 0.0025) and chronicity rate was observed.
Based on the results of five studies a statistically significant
association was found between male gender (OR 1.64, 95% CI
1.06–2.55; P = 0.016) [90,91,108,110,116] and chronicity rate.
Only two studies had examined variation in the prevalence of
HCV chronicity by HBV serostatus, and found no association
(OR 0.99, 95% CI 0.63–1.57; P = 0.978) [91,110]. Furthermore,
the pooled average chronicity prevalence in the studies conducted
in gastroenterology or hepatology units (84%, 95% CI: 74–91) was
significantly higher than in the studies conducted in other settings
(71%, 95% CI: 67–75) (Q-value = 5.292; df = 1; P, 0.021).
Finally, no geographic trends could be detected.
Genotypes
Study questions. What is the genotype distribution in PWID
in Europe, and is it changing over time? What is the proportion of
traditionally ‘difficult to treat’ genotypes (1 and 4)?
Main findings. HCV genotypes 1 and 3, (subtypes 1a and
3a), are the most commonly identified among PWID in Europe.
Genotype 4 may be increasing. The proportion of the more
‘difficult to treat’ genotypes (1+4) showed large variation (17–91%,
median 53%, IQR 43–62%).
Studies included. 43 studies met the inclusion criteria. Data
were available from 20 European countries [81,82,91,92,94–
97,102,103,106,108,111–113,115,120–147]. (Table 4, Figure 4
and Table S5 in Web-appendix S2).
Study design. Eighteen cohort and twenty-five cross-section-
al studies. HCV infection was mainly confirmed by enzyme
immunoassays, immunoblot assays and RT-PCR. HCV geno-
types/subtypes were determined by reverse hybridization assay
and restriction fragment length polymorphisms (RFLPs) assay,
sequencing and other PCR-based methods.
Population. A total of 6,488 HCV-infected PWID were
genotyped or subtyped (range of subjects: 11–865). PWID were: a)
enrolled in drug treatment, screening or national survey programs,
b) regularly monitored in drug treatment centres, or c) hospitalised
in or referred to specified units.
Findings. HCV subtype 1a dominates in Portugal [140],
Spain [142,143] and The Netherlands [113,144], while it is also
common in the Czech Republic [97] and the UK [81,115,145].
HCV subtype 1b prevails in Bulgaria [95], Czech Republic [122],
Estonia [123] and Romania [111].
HCV genotype 2 is relatively uncommon with the exception of
Greece [106,132], Lithuania [138], Sweden [112] and the UK
[82,145,147]. Genotype 3 predominates in Greece [106,129,
130,133,134], Poland [139] and Slovenia [141] and is common in
Austria [120], Belgium [91], France [103,125] and Italy
[136,137]. Subtype 3a dominates in Belgium [92], Cyprus [96]
and France [102,124]. In Ireland, HCV genotypes 1 and 3 are
equally distributed (48%) [108].
Levels of genotype 4 are particularly high in Southern European
countries (Greece [130,133,134], Italy [136,137], Portugal [140]
and Spain [142,143]) compared to Western ones (France
[102,125], Belgium [91,92] and The Netherlands [113,144].
The lowest rates of genotype 4 were reported in Lithuania [138],
Sweden [112], Czech Republic [97,122], and UK [146,147]).
Genetic diversity of genotype 4 suggests that this genotype is
emerging among PWID and among the general population (e.g.
4a in Portugal [140] and Germany [127,128], 4d in Portugal [140]
and The Netherlands [113] and 4f in Italy [137]). Overall, the
proportion of ‘difficult to treat’ genotypes (1+4) varies strongly,
from 17% in Lithuania to 76–91% in the Czech Republic
(Table 4) with a median of 53% (range 17–91%, IQR 43–62%).
Increasing levels of mixed infections are observed, by either
different HCV genotypes (Italy 1b/3a [137], Germany 2a/3b
[128] and Sweden 1a/2b, 1b/2a, 1a/4, 1b/2b [112]) or different
subtypes of the same genotype (Spain 2a/2c and 4c/4d [143],
Belgium 4c/4d [92], The Netherlands 2a/2b [113], and Sweden
2a/2b [112]). This is most likely due to the implementation of
newer line probe assays with higher capability in detecting HCV
subtypes.
Figure 2. Incidence of HCV infection in PWID (per 100 person years).
doi:10.1371/journal.pone.0103345.g002
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HIV co-infection
Study questions. What is the prevalence of HIV among
PWID with HCV infection (HIV-HCV co-infection prevalence) in
Europe?
Main findings. Available data for 22 countries in Europe
suggest considerable variation in the HIV-HCV co-infection
prevalence (0–70%, median 3.9, IQR 0.2–28) among PWID
(Table 4, Figure 5), with this being correlated (correlation
coefficient = 0.98) with the HIV prevalence among PWID, but
generally a median of 15% (IQR 0.0–49%) relatively greater.
Studies included. Sixty-two studies [22,61,71,82,86,92,9
6,98,99,103,106,109,111,116,118,122,129,132,134,146,148–189]
met the inclusion criteria giving 80 HIV-HCV co-infection
estimates. (Table S6 in Web-appendix S2).
Study design. Studies either involved diagnostic testing or
cross-sectional samples of PWID from a variety of settings
involving different sampling methods such as respondent driven
sampling, exhaustive sampling and snowball sampling. HCV
infection status was not confirmed by RNA status in many studies
and so antibody prevalence was used across all studies.
Figure 3. Chronicity of HCV: RNA prevalence (%) among antibody-positive PWID.
doi:10.1371/journal.pone.0103345.g003
Figure 4. Proportion (%) of HCV infections among PWID that are genotypes 1 or 4.
doi:10.1371/journal.pone.0103345.g004
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Population. PWID were recruited from drug treatment
centres, opiate substitution treatment centres, needle and syringe
programmes, hospitals, and prisons.
Findings. Many European countries had multiple estimates
of HIV and HCV prevalence but few recorded HIV-HCV co-
infection prevalence (HIV prevalence among HCV antibody
positives). Estimates of HIV-HCV co-infection prevalence were
available for 22 countries in Europe with thirteen countries having
multiple estimates (Belgium, Czech Republic, Denmark, France,
Germany, Greece, Hungary, Italy, Latvia, Poland, Slovenia, Spain
and UK). The HIV-HCV co-infection prevalence ranged between
0% and 70% in the different countries (median 3.9, IQR 0.2–28).
Co-infection prevalences were low (,= 4%) in 11 countries
(Austria, Bulgaria, Cyprus, Czech Republic, Denmark, Greece,
Hungary, Luxembourg, Romania, Slovenia and UK), moderate (4
to 15%) in three countries (Belgium, Germany and Lithuania) and
high (.15%) in eight countries (Estonia, France, Latvia, Italy,
Netherlands, Poland, Portugal and Spain). As expected the HIV-
HCV co-infection prevalence is higher in settings with higher HIV
prevalence, with a strong linear correlation existing between each
survey’s HIV prevalence estimate and the corresponding HIV-
HCV co-infection prevalence estimate (correlation coeffi-
Figure 5. Proportion (%) of HCV-infected PWID that are co-infected with HIV.
doi:10.1371/journal.pone.0103345.g005
Figure 6. Proportion (%) of HCV positive PWID (antibody or RNA) undiagnosed.
doi:10.1371/journal.pone.0103345.g006
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cient = 0.98), with the HIV-HCV co-infection prevalence being a
median of 15%(IQR 0.0–49%) relatively greater than the HIV
prevalence. No clear relationship existed between HCV preva-
lence and the HIV-HCV co-infection prevalence.
Diagnosis
Study question. What percentage of HCV-infected PWID
are undiagnosed in Europe?
Main findings. Among the studies included, a high propor-
tion of HCV infections in PWID were undiagnosed (median 49%,
range 24–76, IQR 38–64) (Table 4, Figure 6).
Studies included. Eleven studies reported on the proportion
of PWID with undiagnosed hepatitis C infection from five
countries in the EU [114,170–172,180,190–195]. (Table 4 and
Table S7 in Web-appendix S2).
Study design. Ten cross-sectional studies and one retrospec-
tive cohort study. All studies were observational and performed in
non-clinical settings.
Population. Ten studies among PWID in specialised treat-
ment centres and other drug services, one study among PWID
attending general practices.
Findings. The proportion of infections in PWID that were
previously undiagnosed ranged from 24% to 76% with a median
of 49% (IQR 38–64%, n = 13,561).
Treatment
Study question. What is the proportion entering antiviral
treatment among diagnosed cases of chronic HCV infection in
PWID?
Main findings. In six observational studies with non-clinical
recruitment settings, the proportion of PWID diagnosed with
chronic HCV infection that started antiviral treatment was
generally low, at 1–19% (median 9.5, IQR 3.5–15) (Table 4,
Figure 7).
Studies included. Twenty-six studies from 11 countries
fulfilled the inclusion criteria [22,59,79,103,105,107,114,115,
126,131,146,152,165,188,196–206] (Table 4 and Table S8 in
Web-appendix S2).
Study design. Eight were retrospective cohort studies; 11
were prospective cohort studies; one a randomised controlled trial;
one a semi-experimental intervention study and five were cross-
sectional studies. Overall, 16 were observational, whereas 10 were
intervention studies (one study included both observational and
intervention data).
Population. PWID were either patients attending hospitals or
specialist services for hepatitis treatment (‘clinical’ – eight studies),
or recruited through PWID specific services, general practice and/
or community settings (‘non-clinical’ – 18 studies).
Findings. The proportion of PWID with diagnosed chronic
infection entering antiviral treatment was 1–19% (median 9.5,
IQR 3.5–15) in six non-clinical observational studies (four
countries, total sample size 3,017) [105,107,152,196,199,201].
An increasing proportion is seen by setting and study type with
progressively selected study populations, with a median of 23%
(IQR 17–31) in nine intervention non-clinical studies, 28% (IQR
24–42) in seven observational clinical studies [22,103,115,131,
198,200,204] and 47% in one intervention clinical study [126].
Four studies with non-clinical recruitment settings provided a
proportion of antibody positive PWID self-reporting having ever
been treated, with a median of 4.7% (3.4–37, IQR 4.3–13,
n = 868) [79,146,165,202]. Three observational studies with non-
clinical recruitment settings provided the proportion of diagnosed
PWID referred to a specialist for treatment evaluation (median
57%, range 9.0–59) [79,196,201], as did four intervention studies
in non-clinical settings (median 59%, range 21–93, IQR 40–78)
[146,197,205,206].
Burden of disease
Study questions. What estimates exist of the future burden
of disease among PWID with HCV in Europe?
Main findings. The crude mortality rate (CMR) for all-cause
mortality ranged from 2.1–12 cases /100PY. Modelling studies
Figure 7. Proportion (%) of HCV-infected PWID entering antiviral treatment in observational studies in non-clinical settings.
doi:10.1371/journal.pone.0103345.g007
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project an increase in the burden of liver disease. HCV treatment
could reduce this burden and is cost-effective (Table 4).
Studies included. Four observational studies, two modelling
studies and one cost-effectiveness study [177,207–211] (Table 4
and Tables S9–S10 in Web-appendix S2).
Study design. All cohort studies had a prospective design and
one also included retrospective data. Study settings varied from
single centre to nationwide.
Population. PWID were recruited from HIV centres and
through drug treatment centres.
Findings. During 33,284 PY of follow-up 895 of 5,340 PWID
died. The prevalence of HIV co-infection varied between 16%
[209] and 100% [207,208].
All studies reported all-cause CMR, ranging from 2.1 to 12
cases /100PY, (Table S9 in Web-appendix S2). A Danish study
[207] found comparable CMR for those with chronic HCV and
spontaneous resolvers, whereas a study from The Netherlands
[209] observed a two-fold higher CMR for chronically HCV-
infected PWID compared to spontaneous resolvers. The Danish
study [207] reported a .4 times higher CMR than the other
studies. Two studies reported liver-related CMR [207,209], of
0.11 and 3.0/100PY respectively.
Two modelling studies were included, from The Netherlands
[210] and the UK [211], (Table S10 in Web-appendix S2).
Between 2011 and 2025, the HCV-related liver disease prevalence
in The Netherlands was projected to rise by 36% [210]. In
Scotland, [211] a 56% increase in cirrhosis and 64% in moderate
liver disease between 2010 and 2025 was projected. Both studies
showed that HCV treatment could reduce the future liver disease
burden.
One cost-effectiveness analysis from the UK, based on a
dynamic model of HCV transmission and disease progression
[28], found that in a steady state epidemic with HCV prevalence
among PWID of 20% or 40%, HCV treatment of PWIDs was
more cost-effective than treating non/ex-PWIDs with an incre-
mental cost-effectiveness ratio of 599 and 2,920 euro, respectively,
per quality adjusted life year as compared to no treatment.
Discussion
Our study suggests that availability of key data for informing the
scale-up of HCV treatment for PWID in Europe is highly variable,
but diagnosis and treatment uptake remain low. To our
knowledge, this is the first attempt to provide a comprehensive
and comparative review of data for HCV treatment scale-up
among PWID in a large number of countries.
While most countries have information on the genotype
distribution and HIV-HCV co-infection prevalence in PWID
(22/27 countries), only six countries have estimates for five or
more of the seven topic areas reviewed here (Denmark, France,
Ireland, The Netherlands, Spain and UK). In addition, available
data are often based on selected subpopulations (e.g. clinical) and
local studies, which might not be representative for all PWID
living in a country, while in some of the topic areas recent data
(collected since 2006) are scarce. Our review reveals serious gaps
in data availability and comparability, suggesting that many
countries in Europe may not yet have invested sufficiently in
studies or surveillance systems to guide HCV treatment and
prevention policies for PWID. Moreover, although we did not
systematically evaluate the quality of data, we observed large
differences in methods and definitions, likely affecting compara-
bility across data sources [212]. Importantly, the limited data
suggest that overall there are poor levels of diagnosis and
treatment uptake among HCV-infected PWID.
Although diagnosis is a pre-condition for treatment entry and
under-diagnosis an important reason for non-treatment [34], we
found information on the undiagnosed fraction in PWID in only
five countries (19%). The proportion undiagnosed was over 50%
in five of the 11 studies (overall median 49%, range 24–76%),
while methods were not always clear or comparable.
More countries (11/27, 41%) had data on antiviral treatment
access among PWID (note: among those diagnosed). However,
only four countries had studies in non-clinical settings that were
non-interventional (i.e. did not specifically attempt to enhance
treatment access). Among the studies in these countries, the
median proportion of diagnosed PWID who had actually started
treatment was 9.5% (range 1–19%). Interestingly, the proportion
entering treatment increased with the level of selection of the study
population (with a median of 23% in nine non-clinical interven-
tion studies, 28% in seven clinical observational studies and 47%
in one clinical intervention study) suggesting that potentially
higher treatment rates may be achieved with specific interventions.
However, even in the most selected intervention studies a large
proportion of diagnosed PWID remained untreated.
The median proportion of antibody-positive PWID who self-
reported lifetime treatment uptake for HCV in four non-clinical
studies (4.7%), although within a large range (3.4–37%), was
roughly similar to that in two studies in the US, which found a
lifetime uptake of 4.8% among RNA-positive PWID [20] and of
6% among antibody positive PWID [15]. An Australian study
found a self-reported life-time treatment uptake of 10% and an
increasing trend in the annual treatment uptake (0.5% in 1999–
2% in 2011) among HCV antibody-positive PWID [19]. A recent
study in UK used a novel method based on laboratory data to
estimate HCV treatment uptake and outcomes, however was
unable to obtain information by risk group [213].
Referral of chronically infected PWID from non-specialist to
specialist care was found to be incomplete, explaining part of the
low treatment access. However, this was reported by only three of
the observational studies in non-clinical settings (median 57%,
range 9–59) and was found to be similar in four (non-clinical)
intervention studies (59%, range 21–93). The limited treatment
uptake may finally also be due to the absence of national treatment
policies for PWID (Table 4) and/or a decision to wait for the new
potent direct-acting antiviral agents (DAA).
Treatment outcomes are determined by patient characteristics,
which traditionally include HIV co-infection and HCV genotype
[22,36,214]. Although in principle both may soon be less relevant
[36,214,215], it remains to be seen if the much higher costs of
treatment for the unfavourable genotypes and DAA may hamper
their scale-up for PWID in many countries [30,216]. Data on these
two topic areas were more abundant with 20 countries (74%)
having information on genotype distributions and 22 on HIV co-
infection in PWID. The data suggest important variation in
genotypes across countries in Europe, with large variation in the
proportion of ‘difficult to treat’ genotypes among PWID (sum of
percentages of genotypes 1 and 4), ranging from 17% in Lithuania
to 76–91% in the Czech Republic (median 53%). Genotypes 1 and
3, especially subtypes 1a and 3a, are common and have
demonstrated exponential growth during the 20th century [217].
Genotype 4 has been spreading in Western Europe since the 1960s
[217]. It appears to be genetically diversifying and increasing in
particular among PWID in Europe [46,113,128,137,140,144,218–
220]. Countries with predominance of genotypes 1 and high or
increasing levels of genotype 4 face more difficulties in treating
PWID with peginterferon and ribavirin. High levels of HIV co-
infection (over 4%) were found in 11 countries, with levels over
HCV among People Who Inject Drugs in Europe
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15% being found in eight of these (Estonia, France, Italy, Latvia,
The Netherlands, Poland and Portugal, Spain).
Future treatment needs among PWID, especially for ‘treatment
as prevention’, will not only depend on the current prevalence of
chronic infection, but importantly on the incidence of new
infections and re-infection. Incidence estimates of new infections in
PWID based on direct methods were located for only nine
countries (33%) and suggested wide variation in infection rates
(2.7–66/100PY overall and 5.2–42/100PY among current and
recent PWID) whereas just three countries have reported re-
infection rates (0–6.9/100PY), although these are likely to be
underestimates of the real re-infection rate [53,221]. The countries
at highest (Sweden) and lowest (Netherlands) incidence appear to
confirm a previous, prevalence-based, analysis suggesting a link
with prevention policies (Figure 2) [42]. Chronicity levels among
PWID were found for 12 countries (44%) showing a large range
(53–97%). Multiple studies at these extremes (six below 60%, two
above 90%, out of 28) suggest substantial differences in
progression to chronic infection may exist between countries,
which might be explained by differences in gender and HIV co-
infection prevalence distributions between study populations and
the setting of the study, and may impact future treatment needs.
To actually estimate future treatment needs, modelling studies
are important, particularly for assessing the potential impact of
treatment on prevention. Only two of the 27 countries appear to
have carried out a modelling study to estimate the effect of HCV
treatment on the future burden of disease. Without treatment, a
study in The Netherlands (Amsterdam) projected a 36% increase
in the burden of liver disease between 2011 and 2025, whereas in
Glasgow this was projected to be 56–64% for 2010–2025. Both
studies included competing mortality in their model and showed
that HCV treatment would substantially reduce this liver disease
burden.
Mortality in PWID with HCV infection is dependent on
competing mortality (e.g. HIV or drug-related death [222–224])
and duration of persistent HCV infection. The all-cause mortality
rates were estimated at 2.1–2.4/100PY in Spain and The
Netherlands, but were 12.2/100PY among HIV co-infected
PWID in Denmark. The high rate in the Danish study could be
explained by high rates of overdose mortality [49] or differences in
cART initiation, given that a Spanish study reported a CMR of
2.4/100PY among HIV co-infected PWID during a comparable
study period. This suggests significant country differences for
PWID with HCV, in line with findings on mortality among all
PWID [224] and the importance of obtaining country-specific
mortality estimates. Available data on the morbidity and mortality
risk due to HCV among PWID are scarce but are urgently needed
for future planning.
The data reported here are related to the EU and therefore our
results are most probably not generalisable to other regions
globally. However, it is likely that data availability in low and
middle income countries will be lower, despite the often more
serious epidemiological situation among PWID regarding blood-
borne infections e.g. in Eastern Europe and Central Asia
[33,43,225–227]. Our study provides a framework and method-
ology for combining a series of complementary systematic reviews
using standardised and validated methods that may be applied to
other regions, or topic areas, where a comprehensive view may be
beneficial [57], for example when the aim is to support national
public health policies. We are unaware of a similar systematic
review of the literature comparing multiple related topic areas
around a key public health issue in a large number of countries.
Our study is subject to important limitations. We have primarily
focused on published studies, available through the MEDLINE,
EMBASE and the Cochrane Library databases, which are subject
to publication bias and delay. To minimise this problem, we
contacted a network of drug and infectious disease experts in
Europe, to identify missed studies and we included publications in
all languages. Another limitation relates to our inclusion criterion
of having an unselected population of PWID with regard to gender
Figure 8. HCV antibody prevalence (%) among PWID injecting,2 years in the EU, 2006–2011. Note Figure 8: Source EMCDDA, 2013.
(http://www.emcdda.europa.eu/stats13#inf:displayTables); black squares are data with national coverage, blue triangles are data with sub-national
(local, regional) coverage.
doi:10.1371/journal.pone.0103345.g008
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or HBV/HIV infection and to restricting our review to data of
PWID (ever injectors) only. There are many more reports on
populations of people who use drugs where injection status is not
known or that are limited to HIV co-infected patients which we
could mostly not include, although we believe by being restrictive
we may have minimised potential bias. We were also mostly
(except for Incidence) unable to distinguish studies based on ever
or recent (active/current) injectors as this information was usually
not available. However, as most of our outcomes relate to HCV
chronicity we believe the data here presented are not seriously
affected by recent injecting status of the ever PWID in our study
and ever-PWID are the more appropriate group to study. Data in
the Diagnosis and Treatment sections would ideally have been
adjusted for duration of follow-up in the studies, however these
data were mostly not available for the data we extracted. Our data
are further limited regarding the comparability of studies found. In
particular the geographic coverage of studies was usually partial,
with few national studies (Table 4), and they were often
undertaken in health services; so participants may not be
representative of all PWID. Thus some of the differences between
and within countries found here may reflect differences in study
design and methodologies rather than true differences. Finally, we
selected the topic areas for our review on the basis of informed
expert discussions among the authors on what are the key data
elements for treatment scale-up that are not available from routine
monitoring (Table 1 and Table S2). Further work may be
necessary to develop consensus guidance on the information
needed to guide HCV treatment policies.
In this review we focused on data from the literature, as a
complement to data on HCV infection that is routinely collected
by EU bodies, and is likely to be used in national policy decision
making. The routine data include hepatitis C notifications, HCV
antibody prevalence among PWID, PWID population size, HIV
prevalence in PWID (as a proxy for co-infection levels), and the
provision and coverage of needle and syringe programmes and
opioid substitution treatment as primary HCV prevention
measures for PWID (Table S2 in Web-appendix S1). Although
some of these data are widely available, for example most
countries have an estimate of HCV antibody prevalence among
PWID [43,44,49], other available data can be difficult to interpret.
Acute hepatitis notifications are likely to represent only a very
small proportion of real incidence, due to the asymptomatic nature
of acute HCV infection and underreporting [228], while trends in
chronic infections cannot be easily interpreted due to the long time
to diagnosis and their dependence on testing patterns, in addition
to potentially serious underreporting [4,229] and incomplete
availability of risk information. Of particular interest is the HCV
antibody prevalence in new injectors (injecting for less than 2
years) (Figure 8). This may provide a relatively cost-effective
indicator of levels of new infection in PWID [44,192], as an
addition to the regular prevalence data (Figure 9), particularly if it
is supported and regularly validated by incidence studies using
direct methods as here reviewed, or, in addition, indirect methods
[211,230]. Finally, it should be noted that, although population
size estimates of PWID are routinely monitored in Europe [49],
few countries have estimates that are reasonably recent. This
highlights an important need for improvement, given that
population size estimates enable converting data from different
sources into the absolute numbers needed for planning.
In conclusion, the availability of key data for informing the
scale-up of HCV treatment among PWID in individual European
countries is highly variable. Our study suggests that large
proportions of HCV-infected PWID remain undiagnosed, and of
those diagnosed, only one in ten receive antiviral treatment.
Stronger national and international efforts, including operational
research and collection of key data on PWID with HCV, are
needed to develop sound HCV treatment policies for PWID in
Europe.
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